RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$14.51
+0.01 (+0.07%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
-50.76%
YTD
-38.52%
Open$14.79
Previous Close$14.50
Day High$15.07
Day Low$14.07
52W High$39.89
52W Low$12.73
Volume—
Avg Volume8.51M
Market Cap1.47B
P/E Ratio—
EPS$-5.84
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$26.56
Below
SMA 200
$31.06
Below
RSI (14)
37.4
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
26 analysts
Price Target
+413.0% upside
Current
$14.51
$14.51
Target
$74.44
$74.44
$68.49
$74.44 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 701.21M | 570.97M | 933.24M |
| Net Income | -599,094,092 | -439,039,722 | 54.30M |
| Profit Margin | -85.4% | -81.2% | 5.8% |
| EBITDA | -549,083,974 | -424,745,358 | 81.20M |
| Free Cash Flow | — | — | 84.57M |
| Rev Growth | +22.8% | +22.8% | -2.9% |
| Debt/Equity | 3.41 | 3.41 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.96 | -0.02% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $385.65 | +1.55% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.11 | -0.52% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $508.34 | -1.55% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $784.85 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $239.56 | -2.42% | 40.0 | 32.33B |